Fiche société
Neurizon Therapeutics Limited
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| MonepantelThis study is a multicenter, 12-month open label extension study, following Phase 1 Study MON-2021-001, with a single dose of monepantel (MPL) once daily (QD) for the treatment of individuals with MND. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Australia | À vérifier |
| MonepantelThis study is a multicenter, 12-month open label extension study, following Phase 1 Study MON-2021-001, with a single dose of monepantel (MPL) once daily (QD) for the treatment of individuals with MND. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Australia | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Monepantel | Sclérose latérale amyotrophique | Phase 1 | NCT06177431 | An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease | COMPLETED |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Monepantel | Anthelmintic resistance on meat goat properties in Queensland and New South Wales, Australia, with a comparison of statistical methods. | Veterinary parasitology, regional studies and reports | ||
| Monepantel | Evolution of Ivermectin Resistance in the Nematode Model : Critical Influence of Population Size and Altered Emodepside Efficacy. | Evolutionary applications | ||
| Monepantel | Repurposing monepantel in oncology: A conceptual mini-review of proposed mechanisms. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |